Edgewise Therapeutics Inc (EWTX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Edgewise Therapeutics inc   (NASDAQ: EWTX)


Edgewise Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Edgewise Therapeutics Inc's ROI in the second quarter of 2026?
Edgewise Therapeutics Inc recorded a cumulative net loss of $-197 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -38.79%.

Within the Healthcare sector 412 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3439 to 3516.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 2.66 % 14.32 % 5.17 % 9.69 % 18.48 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 451 496 525 562 592
Return On Investment (TTM) -38.79 % -32.36 % -31.77 % -30.67 % -30.43 %
EWTX's Overall Ranking # 3516 # 3439 # 2034 # 3224 # 2844
Seq. Investment Change TTM -6.52 % 2.97 % 3.04 % 3.51 % 4.1 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -197 -176 -168 -157 -151




Return On Investment EWTX's Ranking
Within: No.
Industry # 164
Sector # 413
Overall # 3516

Return On Investment Statistics
High Average Low
-3.34 %
-25.68 %
-38.79 %
(Mar 31 2021)   (Jun 30 2026)







Financial Statements
Edgewise Therapeutics Inc's II. Quarter Investments $ 451 Millions EWTX's Balance sheet
Edgewise Therapeutics Inc's II. Quarter Income $ -57 Millions Quarterly EWTX's Income Statement
EWTX's Income by Division See EWTX's Income by Division


EWTX Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 525 463 323 351 275
Y / Y Investment Growth 13.45 % 43.21 % -7.77 % 27.59 % -
Net Income in Millions -168 -134 -100 -68 -43
Y / Y Net Income Growth - - - - -
Annual Return On Investment -31.95 % -28.9 % -30.98 % -19.3 % -15.58 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EWTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EWTX's Competitors
Subscribers only: Roi for Edgewise Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for EWTX's Customers

Other Ratios
EWTX's Roa EWTX's Inventory Turnover Ratio EWTX's Growth Rates EWTX's Dividend Statistics
EWTX's Profitability Ratios EWTX's Asset Turnover Ratio EWTX's Dividend Growth
EWTX's Roe EWTX's Valuation Ratios EWTX's Financial Strength Ratios EWTX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-08T15:11:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.